ATANIS Biotech, a Swiss biotechnology company specializing in functional allergy diagnosis, announced the successful completion of a significant capital increase. iXLife, a French venture capital fund, co-led the round with US-based AllerFund, the first and only venture capital firm focused on social impact in the food allergy space. Additional investments came from experienced private biotech investors. With the proceeds from the financing, ATANIS will accelerate its product development, scale its services for pharma/biotech customers, and implement its go-to-market strategy.
VISCHER has acted as counsel to ATANIS Biotech in this transaction. The team consisted of partner Gian-Andrea Caprez (pictured left) and associate Sandro Bernet (pictured right, both corporate/m&a).